Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Optimer gets $32.9mm via direct offering

Executive Summary

Anti-infectives company Optimer Pharmaceuticals grossed $32.9mm through a registered direct offering of 2.79mm common shares priced at $10 each (an 8% discount) to institutional investors. The company also sold 457,666 units at $10.93 apiece (a 4% premium) to ProQuest Investments; each unit consists of one common share and one five-year warrant to buy one-fifth of a common share at the same price.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies